News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kyto Biopharma, Inc. Announces High-Affinity Monoclonal Antibody to the Cellular Receptor for Transcobalamin (Vitamin B12)



12/3/2009 11:06:12 AM

Bookmark and Share

TORONTO--(BUSINESS WIRE)--Kyto Biopharma Inc. (OTCBB: KBPH), is a biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES